Colorectal Cancer | Specialty

Numerous Frontline CRC Options Allow Individualized Approach

April 23rd 2016

Given the numerous available treatment options, the most important issue in frontline colorectal cancer care is clarifying the goals of therapy.

Dr. Bekaii-Saab on Active Agents for the Treatment of Colorectal Cancer

April 23rd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses about 2 agents, regorafenib and TAS-102, for the treatment of patients with treat colorectal cancer.

Genomics Studies Opening Up Fresh Options for CRC Research

April 22nd 2016

Raju Kucherlapati, PhD, serves as principal investigator of a Genome Characterization Center as part of The Cancer Genome Atlas program, a National Cancer Institute initiative aimed at defining the copy number changes and structural aberrations present in many different cancer types.

Dr. Berger on Noninvasive Screening Tool for CRC

April 19th 2016

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses a study demonstrating the benefit of utilization of the Cologuard screening test for colorectal cancer (CRC).

Dr. Udit Verma on Regorafenib in Patients With mCRC

April 13th 2016

Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer.

Biomarker Leads to New Potential CRC Treatment

April 13th 2016

Deficiency in the protein NOD-like receptor X1 (NLRX1) could represent a potential biomarker to predict response to therapies in patients with colorectal cancer.

Expert Discusses Microsatellite Instability, Immunotherapy in CRC

April 11th 2016

Zsofia K. Stadler, MD, provides extensive insight on microsatellite instability in colorectal cancer, the biology of and screening for MSI tumors, and the potential impact immunotherapy could have on the treatment paradigm.

Ensituximab Shows Promise in Refractory mCRC

April 8th 2016

Treatment with ensituximab (NPC-1C), a chimeric IgG1 monoclonal antibody, induced stable disease in nearly half of patients with chemotherapy-refractory metastatic colorectal cancer without contributing significant toxicity.

Case Study Suggests Regorafenib Remains Effective Beyond Progression for mCRC

April 5th 2016

Many patients with metastatic colorectal cancer will ultimately progress on standard first- and second-line therapy while maintaining a good performance status, placing importance on the optimal use of third-line treatments.

“Forgotten Lessons” May Help Advance Colorectal Cancer Care

March 31st 2016

Alan P. Venook, MD, shares insight into the evolving treatment paradigm for colorectal cancer.

Dr. Bekaii-Saab on Benefits Associated With Regorafenib for CRC

February 29th 2016

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses the benefits patients receive with regorafenib for the treatment of colorectal cancer.

Potential Biomarkers in Metastatic Colorectal Cancer

February 26th 2016

PI3K-Mutant Metastatic Colorectal Cancer

February 26th 2016

Microsatellite Instability Status in Colorectal Cancer

February 26th 2016

BRAF Testing in Colorectal Cancer

February 26th 2016

Pathways of Resistance in Metastatic Colorectal Cancer

February 26th 2016

Upfront EGFR Therapy in Metastatic Colorectal Cancer

February 26th 2016

EGFR Therapy as Upfront Colorectal Cancer Treatment

February 26th 2016

The Current Status of RAS Testing in Colorectal Cancer

February 26th 2016

Colorectal Cancer: Challenges in Next-Generation Sequencing

February 26th 2016